Investor Presentation

Date: July 28, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 544558 Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and three months ended June 30, 2026. Request you to take the same on record. Thank you. Yours faithfully, For Fabtech Technologies Limited Hemant Mohan Anavkar Executive Director DIN: 00150776 Encl.: As mentioned above FabtechTechnologiesLimited Q1 FY2026-2027 Investor Presentation Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Fabtech Technologies Limited, (The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not a guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Investor Presentation Why Turnkey + In-House Manufacturing Matters In pharmaceutical, biopharma, and healthcare projects, choosing a turnkey partner with in-house Process, Air & Water manufacturing capabilities is no longer a preference, it is a strategic necessity. Single Accountability, Zero Coordination Risk: One partner owns design, engineering, manufacturing, installation, and validation, eliminating delays and vendor conflicts. Precision-Controlled Environments In-House: Process Equipment & Containment Systems (Process), Cleanrooms (Air) & Purified Water & Distribution (Water) are engineered under one ecosystem ensuring seamless integration and regulatory compliance. Speed to Market: In-house manufacturing drastically reduces dependency on imports and fragmented suppliers accelerating delivery, qualification, and commercial launch. Regulatory Confidence: A unified turnkey approach ensures every system meets global cGMP, WHO, EU-GMP, USFDA, and ISO standards from the first blueprint to final validation. Cost Efficiency & Long-Term Reliability: Integrated design-to-delivery reduces project cost overruns and safeguards long-term operational efficiency. IInnvveessttoorr PPrreesseennttaattiioonn Global Turnkey Solutions Provider to the Life Sciences & Healthcare Sectors Fabtech Technologies Limited (FTL), the flagship of the Fabtech Group, brings three decades of engineering excellence to deliver start-to-finish turnkey solutions for pharmaceutical, biotech, and healthcare facilities worldwide. With deep capabilities across Process, Air & Water, FTL integrates design, engineering, manufacturing, and validation to build GMP-compliant, energy-efficient, and contamination-controlled environments across 62 countries. Post-COVID, the MEA region’s focus on pharmaceutical self-reliance has accelerated FTL’s growth trajectory. Derives 78% of revenue from MENA, GCC, and ECO Zone markets, the Company expands through FTS Cleanroom Systems LLC and strategic joint ventures. FTL continues to strengthen its position as a preferred partner for critical facility infrastructure in the markets present. Fabtech’s asset-light, integrated model combines in-house manufacturing, advanced project execution, and minimal third-party dependency to ensure speed, quality, and consistency. By mastering the pillars of Bio-Clean Air, Pure Water, and Precision Process Systems, FTL empowers nations to build resilient, sustainable, and future-ready healthcare manufacturing ecosystems. 100% (KSA) FTL Ecosystem 100% 100% (UAE) Fabtech – Listed Main Board “FABTECH” 49% ~16% 33.33% IInnvveessttoorr PPrreesseennttaattiioonn 01 · THE QUARTER Quarter at a glance ₹74.98 Cr ₹7.41 Cr ₹4.21 Cr 46.7% 01 · THE QUARTER Read it year on year Year on year: the right lens Sequential decline: context matters Revenue up 10.3%, consistent with our growth trajectory Q4 is typically the strongest quarter in EPC businesses Swung from a ₹6.13 Cr loss to a ₹4.21 Cr profit Revenue is recognised on the basis of shipments Contribution margin expanded roughly 910 basis points Seasonal concentration in H2 is characteristic of the sector Employee costs down 2.8% — operating leverage emerging Sequential swings do not reflect order book health Finance costs down 35.9% on post-IPO utilisation of funds Q1 FY27 order inflows and pipeline remain constructive 02 · REVENUE MODEL Revenue follows execution 01 02 03 04 05 06 Tender Order award Engineering & Procurement Execution & Billing & design delivery recognition Revenue recognition happens at the end of a long execution cycle. A quiet Q1 P&L can coexist with a full and healthy project pipeline. Project timing Seasonality pattern Order book quality 03 · FINANCIALS Financial highlights Revenue (₹ Cr) 68.01 74.98 +10.3% Contribution margin 37.6% 46.7% +910 bps EBITDA (₹ Cr) (5.27) 7.41 Positive PAT (₹ Cr) (6.13) 4.21 Positive Employee cost (₹ Cr) 10.52 10.22 −2.8% Finance costs (₹ Cr) 1.34 0.84 −35.9% 03 · FINANCIALS Why the margin matters What drives the improvement 46.7% Better project selection Procurement efficiency Contribution margin, Q1 FY27 — the highest level we have recorded. Execution quality Scope mix 04 · MARKETS order book and Pipeline Becoming local, market by market SAUDI ARABIA AFRICA +130% ₹27.93 Cr Turnaround Headwinds ₹17.13 Cr in Q1 FY27 Morocco and Kenya combined Standalone, on a YoY basis Severe regional pressure 04 · MARKETS Geographic revenue mix 29.6% 27.9% 18.2% 10.0% 9.6% 4.8% Rest of world UAE Saudi Arabia India Kenya Morocco International revenue share of approximately 55 [Showing first 8,000 characters — download PDF for full document]